<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320847">
  <stage>Registered</stage>
  <submitdate>18/11/2009</submitdate>
  <approvaldate>23/11/2009</approvaldate>
  <actrnumber>ACTRN12609001013257</actrnumber>
  <trial_identification>
    <studytitle>Methylphenidate for Borderline Personality Disorder in Adolescents</studytitle>
    <scientifictitle>An open-label trial to evaluate the effect of the psychostimulant Methylphenidate on the severity of Borderline Personality Disorder in Adolescents.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Borderline Personality Disorder (BPD)</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All eligible patients will receive methylphenidate IR (immediate release oral tablet) treatment for 12 weeks, at an initial dose of 0.5mg/kg/day, correct to the
nearest 5mg, in 2 divided doses, and increased over 4 weeks, at the discretion of the researcher based on the severity of illness and response to the prescribed dose; to a maximum of 1mg/kg/day in 3 divided doses.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Global Impression Scale-Severity (CGI-S), measuring symptom severity and degree of interpersonal functioning.</outcome>
      <timepoint>Before treatment, at the end of 12-week treatment trial, and after a further 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adolescent females with a diagnosis of Borderline Personality Disorder</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Comorbid diagnosis of Autistic Spectrum Disorder, clinically evident mental retardation or a tick disorder.
- Comorbid diagnosis of a significant medical disorder, such as active hepatic or renal disease, dementia, serious head injury or active cancer.
- Marked previous or current anxiety or psychotic symptoms.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>The proposed sample will be 30 female adolescent patients with BPD. Patients will be recruited from adolescent outpatient clinics in the inner western suburbs of Sydney.</concealment>
    <sequence>No randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>18/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Concord Hospital, Department of Psychiatry</primarysponsorname>
    <primarysponsoraddress>Hospital Rd
Concord West NSW 2138</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Concord Hospital, Department of Psychiatry</fundingname>
      <fundingaddress>Hospital Rd
Concord West NSW 2138</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress>n/a</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study draws on the observation that there are genetic, clinical and neuropsychological similarities between Borderline Personality Disorder (BPD) and Attention-Deficit/Hyperactivity Disorder (ADHD). Since psychostimulants such as methylphenidate are the mainstay of treatment of ADHD, it is proposed that psychostimulants be trialed in a population of female adolescents with BPD, with the intention of enhancing our understanding of BPD and providing a novel treatment option for this difficult-to-treat condition. 
Hypothesis: That selected patients with BPD will respond positively to a trial of methylphenidate.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>HREC/09/CRGH/219</hrec>
      <ethicsubmitdate>21/10/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Georgios Liangas</name>
      <address>Redbank House
Institute Rd
Westmead NSW 2145</address>
      <phone>+61 2 9845 6577</phone>
      <fax />
      <email>georgios.liangas@swahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Georgios Liangas</name>
      <address>Redbank House
Institute Rd
Westmead NSW 2145</address>
      <phone>+61 2 9845 6577</phone>
      <fax />
      <email>georgios.liangas@swahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>